NasdaqGS - Delayed Quote • USD
Voyager Therapeutics, Inc. (VYGR)
At close: April 18 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 10 | 9 |
| Avg. Estimate | -0.44 | -0.47 | -1.8 | -1.73 |
| Low Estimate | -0.52 | -0.67 | -2.9 | -4.18 |
| High Estimate | -0.31 | -0.32 | -0.6 | 0.15 |
| Year Ago EPS | 2.94 | -0.51 | 2.97 | -1.8 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 10 | 9 |
| Avg. Estimate | 9.41M | 7.29M | 38.84M | 54.1M |
| Low Estimate | 5M | -- | 5M | -- |
| High Estimate | 16M | 16M | 90.14M | 154.92M |
| Year Ago Sales | 150.48M | 4.85M | 250.01M | 38.84M |
| Sales Growth (year/est) | -93.70% | 50.20% | -84.50% | 39.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.77 | -0.57 | -0.58 | -0.29 |
| EPS Actual | 2.94 | -0.51 | -0.59 | 1.25 |
| Difference | 2.17 | 0.06 | -0.01 | 1.54 |
| Surprise % | 281.80% | 10.50% | -1.70% | 531.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.44 | -0.47 | -1.8 | -1.73 |
| 7 Days Ago | -0.44 | -0.47 | -1.8 | -1.73 |
| 30 Days Ago | -0.47 | -0.49 | -1.86 | -1.87 |
| 60 Days Ago | -0.25 | -0.63 | -1.84 | -1.28 |
| 90 Days Ago | -0.25 | -0.63 | -1.84 | -1.28 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | VYGR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -115.00% | -- | -- | 0.80% |
| Next Qtr. | 7.80% | -- | -- | 9.60% |
| Current Year | -160.60% | -- | -- | 4.50% |
| Next Year | 3.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Initiated | Guggenheim: Buy | 3/26/2024 |
| Initiated | HC Wainwright & Co.: Buy | 3/19/2024 |
| Initiated | Citigroup: Buy | 3/7/2024 |
| Upgrade | Wells Fargo: Equal-Weight to Overweight | 1/2/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 8/7/2023 |
| Maintains | Canaccord Genuity: Buy to Buy | 5/10/2023 |
Related Tickers
QURE uniQure N.V.
4.7100
+0.86%
RGNX REGENXBIO Inc.
16.11
-5.40%
EWTX Edgewise Therapeutics, Inc.
15.45
-1.28%
PBYI Puma Biotechnology, Inc.
4.9900
-3.48%
NKTX Nkarta, Inc.
7.79
-0.89%
ADAP Adaptimmune Therapeutics plc
0.8984
-8.98%
KURA Kura Oncology, Inc.
17.68
-1.72%
HRMY Harmony Biosciences Holdings, Inc.
29.03
-0.55%
CPRX Catalyst Pharmaceuticals, Inc.
15.34
-4.12%
ACAD ACADIA Pharmaceuticals Inc.
17.07
-0.70%